Mortality After Multivessel Revascularization in Patients With Diabetes and Acute Coronary Syndromes
While CABG was associated with reduced all-cause mortality compared to multivessel PCI in patients with diabetes and NSTEMI, CABG benefit was seen only against PCI patients potentially ineligible for CABG after receiving a preprocedure surgical consultation.
Authors
- José Carlos Nicolau (ORCID: https://orcid.org/0000-0002-9680-3689)
- Dennis T. Ko (ORCID: https://orcid.org/0000-0001-6840-8051)
- Feng Qiu (ORCID: https://orcid.org/0000-0001-9882-7564)
- Lucas C. Godoy (ORCID: https://orcid.org/0000-0001-6171-1269)
- Harindra C. Wijeysundera (ORCID: https://orcid.org/0000-0001-8464-1080)
- Maneesh Sud (ORCID: https://orcid.org/0000-0003-1936-5133)
- Peter C. Austin (ORCID: https://orcid.org/0000-0003-3337-233X)
- Patrick R. Lawler (ORCID: https://orcid.org/0000-0001-5155-5071)
- Derrick Y. Tam (ORCID: https://orcid.org/0000-0002-3060-7108)
- Michael E. Farkouh (ORCID: https://orcid.org/0000-0002-8095-0246)
- Douglas S. Lee (ORCID: https://orcid.org/0000-0001-7078-745X)
- Karin H. Humphries (ORCID: https://orcid.org/0000-0002-9933-622X)
- Rodolfo V. Rocha (ORCID: https://orcid.org/0000-0002-1009-2063)
- Baiju R. Shah (ORCID: https://orcid.org/0000-0003-3598-3628)
- Mario Gaudino (ORCID: https://orcid.org/0000-0003-4680-0815)
- Stephen Edward Fremes (ORCID: https://orcid.org/0000-0003-1723-3049)
Institutions
- Sunnybrook Health Science Centre (CA)
- University Health Network (CA)
- University of British Columbia (CA)
- University of Toronto (CA)
- Cornell University (US)
- McGill University Health Centre (CA)
- Health Sciences Centre (CA)
- Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (BR)
- Institute for Clinical Evaluative Sciences (CA)
- Sinai Health System (US)
- Weill Cornell Medicine (US)
Publication Details
- Journal
- JACC Advances
- Published
- 2024-09-01
- DOI
- https://doi.org/10.1016/j.jacadv.2024.101203
- Citations
- 1
- Primary Topic
- Coronary Interventions and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 0.57
Funders
- Amgen
- AstraZeneca
- Sanofi
- CSL Behring
- Boston Scientific Corporation
- University of Toronto
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
- Novo Nordisk
- Esperion Therapeutics
- National Institutes of Health
- Canadian Institutes of Health Research
- Daiichi Sankyo Europe